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Transcriptional activation of the nuclear recep-
tor RAR by retinoic acid (RA) often leads to inhi-
bition of cell growth. However, in some tissues,
RA promotes cell survival and hyperplasia,
activities that are unlikely to be mediated by
RAR. Here, we show that, in addition to func-
tioning through RAR, RA activates the ‘‘orphan’’
nuclear receptor PPARb/d, which, in turn, in-
duces the expression of prosurvival genes.
Partitioning of RA between the two receptors
is regulated by the intracellular lipid binding
proteins CRABP-II and FABP5. These proteins
specifically deliver RA from the cytosol to nu-
clear RAR and PPARb/d, respectively, thereby
selectively enhancing the transcriptional activ-
ity of their cognate receptors. Consequently,
RA functions through RAR and is a proapoptotic
agent in cells with high CRABP-II/FABP5 ratio,
but it signals through PPARb/d and promotes
survival in cells that highly express FABP5. Op-
posing effects of RA on cell growth thus ema-
nate from alternate activation of two different
nuclear receptors.
INTRODUCTION
The vitamin A metabolite retinoic acid (RA) regulates mul-
tiple biological processes and plays key roles in embry-
onic development and in tissue remodeling in the adult.
It is well established that many of the activities of RA are
mediated by retinoic acid receptors (RARa, b, and g), li-
gand-inducible transcription factors that are members of
the superfamily of nuclear hormone receptors (Laudet
and Gronemeyer, 2002). RARs associate with the retinoid
X receptor (RXR) to form heterodimers that bind to regula-
tory regions of specific target genes and modulate tran-scriptional rates in response to their cognate ligands
(Chambon, 1996; Mangelsdorf et al., 1994). Transcrip-
tional activation by RAR may trigger differentiation (Park
et al., 1999; Rochette-Egly and Chambon, 2001), cell-
cycle arrest (Donato et al., 2007), and apoptosis (Altucci
et al., 2001; Donato and Noy, 2005; Kitareewan et al.,
2002), and thus often leads to inhibition of cell prolifera-
tion. Accordingly, RA displays distinct anticarcinogenic
activities and is currently used in or is being tested as
a therapeutic agent in several human cancers (Soprano
et al., 2004).
However, in some tissues,RAappears topromote rather
than inhibit cell survival. For example, RA is critical for
neuronal survival (Henion and Weston, 1994; Jacobs
et al., 2006; Plum et al., 2001; Rodriguez-Tebar and
Rohrer, 1991), and it was reported that RA treatment can
enhance skin tumor formation (Verma et al., 1982). RA is
essential for normal keratinization in various epithelia (Wol-
bach and Howe, 1978), and topical administration of the
hormonestimulatesdermal repair and induceshyperprolif-
eration of basal kertinocytes (Kang et al., 1995; Zouboulis,
2001). Interestingly, although RA plays critical roles in
maintenance of skin integrity, mice lacking both RARa
and RARg as well as RARb-null mice display normal kera-
tinocyte proliferation (Chapellier et al., 2002). These obser-
vations indicate that RARs are dispensable for keratino-
cyte renewal and suggest that some RA activities in the
skin are mediated by an RAR-independent pathway.
We previously reported that RA binds with a high affinity
to another nuclear receptor, namely PPARb/d, a member
of a subclass of receptors, which also includes PPARa
and PPARg, and that, like RAR, functions as a heterodimer
with RXR (Laudet and Gronemeyer, 2002). Selective asso-
ciation of RA with PPARb/d was suggested by the obser-
vations that the Kd for RA binding by this receptor is
15 nM, about an order of magnitude stronger than that
displayed by PPARa and PPARg. Correspondingly, in the
context of a reporter gene construct, RA was found to effi-
ciently activate PPARb/d but not PPARa or PPARg (Shaw
et al., 2003). Hence, an intriguing possibility is that, in
some cells, RAmay activate transcription not only throughCell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc. 723
RAR but also through PPARb/d. It is noteworthy in regard
to this that, in keratinocytes, PPARb/d induces differentia-
tion and, importantly, displays pronounced antiapoptotic
activities mediated in part by direct transcriptional target-
ing of the PDK-1/Akt survival pathway (Di-Poi et al.,
2002; Tan et al., 2004). Consequently, PPARb/d is central
to maintenance of skin permeability-barrier integrity and
to keratinocyte survival during inflammation and wound
healing (Di-Poi et al., 2003; Icre et al., 2006).
Ligands that activate RAR and the various PPAR iso-
types also bind in cells to intracellular lipid binding proteins
(iLBPs), a family of small proteins that share a remarkably
similar three-dimensional structure (Gutierrez-Gonzalez
et al., 2002; Kleywegt et al., 1994; Veerkamp and Maat-
man, 1995) but bind lipophilic molecules with distinct se-
lectivities. Some members of this family, termed cellular
retinoic acid binding proteins (CRABP-I and II), specifically
associate with retinoic acid with subnanomolar affinities
(Dong et al., 1999). Other iLBPs, known as fatty-acid bind-
ing proteins (FABPs), display broad selectivities and bind
a variety of fatty acids and some fatty-acid derivatives. In
fact, the spectrum of ligands that bind to FABPs is reminis-
cent of that of PPARs (Gutierrez-Gonzalez et al., 2002;
Hanhoff et al., 2002; Norris and Spector, 2002; Widstrom
et al., 2001). The shared ligand selectivities of some iLBPs
and some nuclear receptors suggest that specific mem-
bers of the two classes of proteins may cooperate in regu-
lating the biological activities of their common ligands.
Such a cooperation is also suggested by overlapping
tissue-expression profiles and by involvement in similar
biological functions.
Recent studies indeed demonstrated that three iLBPs,
CRABP-II, FABP5 (K-FABP, eFABP, mal1), and FABP4
(A-FABP, aP2), selectively cooperate with the nuclear re-
ceptors RARa, PPARb/d, and PPARg, respectively. Spe-
cifically, these studies established that, upon association
with particular ligands, these binding proteins translocate
from the cytosol to the nucleus, that they engage in direct
protein-protein interactions with their ‘‘cognate’’ recep-
tors, and that the resulting complex mediates ‘‘ligand-
channeling’’ from the binding protein to the receptor. Con-
sequently, the binding proteins facilitate the ligation of the
respective receptors and significantly augment their tran-
scriptional activities (Budhu and Noy, 2002; Dong et al.,
1999; Manor et al., 2003; Sessler and Noy, 2005; Tan
et al., 2002). Interestingly, although FABP4 and FABP5
bind multiple ligands, only particular compounds trigger
their nuclear translocation (Tan et al., 2002). FABP4moves
into the nucleus in response to ligands that activate
PPARg but not upon treatment with PPARb/d ligands. In
contrast, FABP5mobilizes to the nucleus only in response
to ligands that activate PPARb/d.
Hence, available information suggests the possibility
that, while RA inhibits cell-growth by signaling through
RAR, the ‘‘nontraditional’’ proproliferative activities of
this hormone may be mediated by PPARb/d. Work de-
scribed in this manuscript was undertaken in order to ex-
amine this hypothesis and to investigate the possibility724 Cell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc.that CRABP-II and FABP5 control the partitioning of RA
between the two receptors.
RESULTS
RA Facilitates Tumor Growth in the MMTV-neu
Transgenic Mammary Cancer Model
In keratinocytes, RA exerts proproliferative activities that
appear to be mediated by a pathway other than activa-
tion of RAR (Chapellier et al., 2002). In search for an addi-
tional model that will allow for exploring the mechanisms
that underlie ‘‘nontraditional’’ activities of RA, we con-
sidered the transgenic mammary cancer mouse model
TgN(MMTVneu)202Mul (Akagi et al., 1997; Guy et al.,
1992). The oncogenic hallmark of this model is a mam-
mary-specific amplification of the growth-factor receptor
c-erb-B2/neu, which is often amplified in primary human
breast cancers (King et al., 1985). This model, in which
100% of female mice develop mammary adenocarci-
nomas (Muller et al., 1988), was chosen because it has
been reported that overexpression of neu in mammary
carcinoma cells leads to RA resistance, suggesting down-
regulation of RAR signaling (Tari et al., 2002). To examine
the effects of RA on tumor development, the rate of tumor
growth was studied in untreatedmice and inmice system-
ically treated with RA as of age 140 days. Measurements
were initiated when tumors reached a volume of 0.065
cm3. The data (Figure 1A) showed that RA treatment dra-
matically facilitated tumor formation with mean tumor vol-
ume on day 20 of 1.09 ± 0.22 cm3 in untreated mice and
1.87 ± 0.25 cm3 in the RA-treated group (mean ± S.E.M.,
n = 12 in each group, P = 0.04). Assessment of mouse sur-
vival, defined as the time when tumor volume reached
0.524 cm3 (Figure 1B), indicated that, although all mice
eventually developed tumors of that size, the median sur-
vival of RA-treated versus untreated mice was 205 versus
240 days (P = 0.001). Hence, RA exerts proproliferative
activities in tumors that arise in MMTVneu mice.
Subsequent experiments thus utilized two cell lines in
which RA displays ‘‘nontraditional’’ activities, leading to
cell survival and growth: HaCaT keratinocyte cells and
NaF cells, derived from tumors that arise in MMTVneu
mice. For comparison, we employed MCF-7 mammary
carcinoma cells, in which RA is known to function through
RAR and to inhibit cell proliferation (Donato and Noy,
2005; Donato et al., 2007; Mangiarotti et al., 1998; Toma
et al., 1998).
In HaCaT Keratinocytes, RA Activates PPARb/d
in Parallel to Activation of RAR
The ability of RA to activate PPARb/d in the human kerati-
nocyte cell line HaCaT was examined. Transcriptional
activation assays conducted using a luciferase reporter
driven by a consensus PPAR response element (PPRE)
showed that the synthetic PPARb/d-selective ligand
GW0742, but not the RAR-selective ligand 4- ([E]-2-
[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]-
1-propenyl)benzoic acid (TTNPB), induced transcription
Figure 1. RA Facilitates Tumor Growth in
MMTV-neu Mice
Tumor growth was monitored in untreated fe-
male MMTV-neu mice and in mice subjected
to systemic RA as of age 140 days.
(A) Sizes of tumorsweremeasuredwith calipers
with a start point (day 0) of tumor volume =
0.065 cm3. Volumes of tumors in untreated
(open symbols) and RA-treated (closed sym-
bols) on day 20 were 1.09 ± 0.22 cm3 versus
1.87 ± 0.25 cm3 (mean ± SEM; n = 12 in each
group, p = 0.04).
(B) Mice were treated as described in (A), and
survival, defined as the age in which tumor
volume reached 0.524 cm3, was assessed.Me-
dian survivals were 240 and 205 days for un-
treated mice (open symbols) and RA-treated
mice (closed symbols, n = 12 in each group,
p = 0.001).of the reporter (Figure 2A). These observations attest to
the expression and functionality of PPARb/d in these cells
and demonstrate specificity of reporter response. RA also
enhanced the expression of the PPRE-driven reporter and
did so in a dose-responsive manner (Figure 2B). The re-
sponse was markedly suppressed when the expression
of PPARb/d in the cells was decreased by about 80% by
siRNA methodology (Figure 2B), indicating that the ability
of RA to induce reporter expression was indeed mediated
by this receptor and not by RAR.
We then set out to examine the ability of RA to induce
the expression of endogenous PPARb/d target genes in
HaCaT cells. One of these, PDK-1, was previously shown
to comprise a direct PPARb/d target in HaCaT cells (Di-Poi
et al., 2002). Two other genes, fasting-induced adipose
factor (FIAF) (Kersten et al., 2000) and adipose differentia-
tion-related protein (ADRP) (Schmuth et al., 2004), were
reported to be targeted by PPARb/d in other cells. Chro-
matin immunoprecipitation assays demonstrated that
PPARb/d associates with the PPAR response elements
of both FIAF and ADRP in HaCaT cells (Figure S1), verify-
ing that both are direct targets for this receptor in the con-
text of these cells. The PPARb/d ligand GW0742 as well as
RA upregulated the expression of mRNA for all three of
these endogenous PPARb/d target genes (Figure 2C).
The observations that the RAR-ligand TTNPB had little ef-
fect on the expression of these genes further confirm that
RAR is not involved in this activity of RA. As a control, cells
were treated with 9-cis-RA (9cRA), a ligand that activates
RXR, the obligatory heterodimerization partner for both
RAR and PPARs (Levin et al., 1992). This ligand induced
amodest response, which likely emanated from activation
of the RXR moiety of the RXR-PPARb/d heterodimer. The
small magnitude of the response indicates that the induc-
tion of ADRP and FIAF by RA is not a result of conversion
of RA to its 9-cis isomer within the cells. Further support
for the conclusion that upregulation of these genes by
RA is mediated by PPARb/dwas provided by the observa-
tions that an 80% decrease in the expression of thisreceptor significantly hampered the induction of ADRP
by both GW0747 and RA (Figure 2D).
Notably, oneof thePPARb/d targets found tobe induced
by RA, PDK-1, is an important component of the anti-
apoptotic activities of this receptor in keratinocytes, where
induction of this kinase leads to phosphorylation and acti-
vation of the downstream PDK-1-target survival factor Akt
(Di-Poi et al., 2002). The effects of RA or GW0742 on the
phosphorylation level of Akt were thus examined. Treat-
ment with either of these ligands, but not with TTNPB or
9cRA, significantly increased the phosphorylation level of
Akt (Figure 2E).
In addition to activating PPARb/d, RA also upregulated
the expression of a reporter gene construct driven by an
RAR response element (Figure 2F), and it efficiently upre-
gulated the expression of mRNA for CYP26a, a known
direct RAR target gene (Loudig et al., 2000) (Figure 2G).
Hence, in HaCaT cells, RA treatment results in parallel
activation of both RAR and PPARb/d.
FABP5 Translocates into the Nucleus in Response
to RA, and It Enhances RA-Induced,
PPARb/d-Mediated Transcriptional Activation
The observations that RA can activate both RAR and
PPARb/d raise the question of the factors that regulate
the dual activity of this hormone. We previously showed
that the iLBPs CRABP-II and FABP5 mobilize to the
nucleus in response to ligands that activate RAR and
PPARb/d, respectively, and that they bind to their cognate
receptors to form a complex through which the ligand
is directly ‘‘channeled’’ to the receptor. Consequently,
CRABP-II enhances the transcriptional activity of RAR,
while FABP5 facilitates the activation of PPARb/d (Budhu
and Noy, 2002; Donato and Noy, 2005; Dong et al.,
1999; Manor et al., 2003; Tan et al., 2002). The observa-
tions that RA serves as a ligand for PPARb/d thus raise
the possibility that RA may be delivered to this receptor
by FABP5. A fluorescence-based binding assay (Fig-
ure 3A) demonstrated that GW0742 and RA bind toCell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc. 725
Figure 2. In HaCaT Cells, RA Activates Both PPARb/d and RAR
(A and B) Transactivation assays in HaCaT cells transfected with a PPRE-driven luciferase reporter. Cells were treated with the denoted ligands for
15 hr and lysed, and luciferase activity was measured and corrected for b-galactosidase activity. Data were normalized to the basal activity. Data are
mean ±SEM, n = 3. In (A), cells were treatedwith vehicle or GW0742 (GW) or TTNPB (T, 1 mM). In (B), cells were cotransfectedwith either control siRNA
or siRNA for PPARb/d and then treated with RA at the denoted concentrations.
(C) HaCaT cells were treated with denoted ligands (0.1 mM, 4 hr) and RNA extracted. Levels of mRNA of the PPARb/d target genes FIAF, ADRP, and
PDK-1 were analyzed by Q-PCR and normalized to 18s mRNA. Data are mean ± SEM, n = 3.
(D) HaCaT cells were transfected with control siRNA or PPARb/d siRNA (24 hr) and then treated with the denoted ligands (0.1 mM, 4 hr) and RNA ex-
tracted. ADRP mRNA was analyzed by Q-PCR and normalized to 18s mRNA. Data are mean ± SEM, n=3.
(E) Cells were treated with denoted ligands (0.1 mM, 12 hr) and lysed. Thr-307-phospho-Akt, total Akt, and b-tubulin were assessed by immunoblots.
Data from a representative experiment, which was repeated four times with similar results, are shown.
(F) Transactivation assays in HaCaT cells transfected with a RARE-driven luciferase reporter. Cells were treated with RA at the denoted concentra-
tions (15 hr) and lysed, and luciferase activity was measured and corrected for b-galactosidase activity. Data were normalized to the basal activity.
Data are mean ± SEM, n = 3.
(G) Cells were treated with the denoted ligands and expression of mRNA of the RAR target gene Cyp26a analyzed by Q-PCR and normalized to 18s
mRNA. Data are mean ± SEM, n=3.FABP5 with Kds of 42.3 ± 4.5 nM and 34.8 ± 6.6 nM, re-
spectively (mean ± SD, n = 3), in good agreement with
binding affinities of this protein toward other ligands (Tan
et al., 2002). The subcellular localization of FABP5 was
then examined. COS-7 cells were transfected with FABP5
fused to green fluorescence protein (GFP), and confocal
fluorescence microscopy was used to image GFP-
FABP5 in live cells treated with various ligands (Figure 3B).
Similarly to the behavior of GFP when transfected alone,
GFP-FABP5 in untreated cells distributed between the cy-
toplasm and the nucleus, most likely reflecting that over-
expression of the protein leads to leakage into the nucleus
even in the absence of a specific nuclear localization sig-
nal (data not shown and Sessler and Noy [2005]). Treat-
ment of cells with stearic acid, a long chain fatty acid
that binds FABP5 but does not activate it, did not affect
the subcellular distribution of the protein. In contrast,726 Cell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc.treatment with either GW0742 or RA resulted in a distinct
shift of the protein into the nucleus (Figure 3B). To monitor
the effects of ligands on the localization of endogenous
FABP5 in HaCaT cells, cells were treated with vehicle,
RA, or stearate, subjected to subcellular fractionation,
and the presence of FABP5 in cytosol and in nuclei exam-
ined by immunoblots (Figure 3C). The data demonstrated
that endogenous FABP5 in HaCaT cells is predominantly
cytosolic in the absence of ligand and that it accumulates
in the nucleus in response to RA, but not upon treatment
with stearic acid. Hence, like known PPARb/d ligands,
RA activates the nuclear localization of FABP5.
The effects of FABP5 on the ability of RA to activate
PPARb/d were examined by transactivation assay using
COS-7 cells, which express very low level of either
FABP5 or CRABP-II. Cells were cotransfected with a lucif-
erase reporter construct driven by a PPRE, an expression
Figure 3. FABP5 Binds RA, Translocates to the Nucleus in Response to This Ligand, and Enhances RA-Induced Activation of
PPARb/d
(A) FABP5 was titrated with the fluorescent probe ANS. Titrations curves (left panel, filled squares) were corrected for linear nonspecific fluorescence
(solid line at end of titration curve) and corrected data (filled circles) analyzed to yield a Kd of 57 ± 7.3 nM (mean ± SD, n = 3). Kds for the association of
FABP5 with RA (middle panel) and with GW0742 (right panel) were determined by fluorescence competition titrations.
(B) COS-7 cells were transfected with an expression vector harboring GFP-FABP5 and imaged. Images were acquired from live cells before and after
a 30 min treatment with RA (1 mM). Right panel shows quantitation of nuclear/cytoplsmic partitioning of FABP5 in cells treated with denoted ligands.
Forty cells of each treatment group were analyzed (mean ± SEM).
(C) HaCaT cells were treated with RA or with stearic acid (1 mM, 30 min). Nuclei were separated from cytosol by subcellular fractionation (Calbiochem
ProtoExtract Subcellular Proteome Extraction kit) and anlyzed for the presence of FABP5 by immunoblots. Efficiency of fractionation was validated by
immunoblotting for the cytosolic marker GAPDH and the nuclear marker histone 1.
(D) Transactivation assays were carried out in COS-7 cells cotransfected with a luciferase reporter driven by a PPRE and an expression vector for
PPARb/d (left panel) or with an RARE-driven reporter together with an expression vector for RARa (right panel). Cells were also transfected with
an empty vector or with expression vectors for either FABP5 or CRABP-II, treated with RA and lysed, and luciferase activity was determined.
Data are mean ± SEM, n = 3.
(E) HaCaT cells were not transfected or transfected with either control siRNA or a construct harboring FABP5 siRNA (24 hr). The ability of denoted
ligands to induce ADRP expression was monitored by Q-PCR and normalized to 18s mRNA. Data are mean ± SEM, n = 3.vector for PPARb/d, and a vector harboring cDNA for ei-
ther FABP5 or CRABP-II. Cells were then treated with RA,
and the expression of the reporter monitored (Figure 3D,
left panel). RA enhanced the expression of the PPRE-
driven reporter in a dose-responsive manner. While ex-
pression of CRABP-II did not affect the activity, FABP5
significantly enhanced RA-induced, PPARb/d-mediated
transactivation. To investigate the effect of the binding
proteins on RA-induced activation of RAR, cells were
transfected with a luciferase reporter under the control of
an RAR response element (RARE), an expression con-
struct for RARa, and a vector harboring cDNA for either
FABP5 or CRABP-II. In agreement with previous reports,
CRABP-II augmented RA-induced transactivation ofRAR. On the other hand, FABP5 had little effect on this ac-
tivity (Figure 3D, right panel). Cells in which the receptors
were not ectopically expressed displayed qualitatively
similar behaviour, but the magnitudes of the ligand-
induced responses were significantly smaller (not shown).
The involvement of FABP5 in RA-induced activation of
PPARb/d was further investigated by examining the effect
of decreasing the expression level of this binding protein
on the ability of RA to activate the receptor in HaCaT cells.
Cells were transfected with FABP5 siRNA, resulting in an
about 80% decrease in the level of the protein, and induc-
tion of the PPARb/d target gene ADRP was monitored
(Figure 3E). Decreasing the expression of FABP5 mark-
edly attenuated the ability of both GW0742 and RA toCell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc. 727
Figure 4. In HaCaT Cells, Decreasing the
FABP5/CRABP-II Ratio Diverts RA away
from PPARb/d
(A) Expression ofCRABP-II and FABP5 inmam-
mary tumors that arise inMMTVneumice and in
adjacent normal mammary tissue estimated by
immunoblots.
(B) Expression levels of CRABP-II and FABP5 in
HaCaT, NaF, MCF-7, and F9 cells were esti-
mated by immunoblots.
(C) HaCaT cells were transfected with an ex-
pression vector for CRABP-II or with a vector
harboringFABP5siRNA.Effectiveness of trans-
fection in modulating the proteins’ expression
levels was monitored by immunoblotting.
(D) Parental HaCaT cells and HaCaT cells over-
expressing CRABP-II or underexpressing
FABP5 were treated with denoted ligands
(1 mM, 4 hr), and expression of PDK-1 mRNA
was measured by Q- PCR. Data are mean ±
SEM, n = 3.upregulate the expression of the ADRP, further substanti-
ating that the presence of FABP5 is necessary for efficient
activation of PPARb/d by its ligands, including RA.
Decreasing the FABP5/CRABP-II Ratio in HaCaT
and NaF Cells Converts RA from a Survival
Factor to a Proapoptotic Agent
The observations that RA is delivered to RAR by CRABP-II
and is shuttled to PPARb/d by FABP5 suggest that differ-
ential expression profiles of these iLBPs may regulate the
partitioning of RA between the two receptors in different
cells. The levels of the two binding proteins were thus ex-
amined in several tissues and cells. Of special interest are
mammary tumors that arise in the transgenic mouse can-
cer model MMTVneu. RA treatment of MMTVneu mice
facilitates mammary tumor development (Figure 1). On
the other hand, it was previously reported that ectopic ex-
pression of CRABP-II in these tumors induces carcinoma
cell apoptosis and suppresses tumor growth (Manor et al.,
2003), indicating that, under these conditions, RA exerts
growth-inhibitory activities. Comparison between the ex-
pression levels of CRABP-II and FABP5 in tumors that
arise in MMTVneumice and in adjacent normal mammary
tissue revealed that CRABP-II expression is markedly de-
creased, while the level of FABP5 is significantly higher
in the tumors (Figure 4A). Hence, tumor development in
MMTVneu mice is accompanied by a dramatic decrease
in the CRABP-II/FABP5 ratio. Corresponding to this ex-
pression profile in vivo, NaF cells, a cell line derived from
MMTVneu tumors, display a high level of FABP5 and min-
imal expression of CRABP-II (Figure 4B). Similarly, HaCaT
cells, in which RA can function through PPARb/d, express
a high level of FABP5 and an undetectable CRABP-II
content (Figure 4B). In contrast, the mammary carcinoma728 Cell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc.MCF-7 cells, in which RA activates RAR to inhibit cell
growth (Donato and Noy, 2005; Donato et al., 2007; Man-
giarotti et al., 1998; Toma et al., 1998), and F9 teratocarci-
noma cells, which differentiate into primitive endoderm in
response to RA-induced, RAR-mediated signaling (Roch-
ette-Egly and Chambon, 2001; Strickland and Mahdavi,
1978; Strickland et al., 1980), express a markedly higher
CRABP-II/FABP5 ratio (Figure 4B).
The effect of reversing the CRABP-II/FABP5 ratio in
HaCaT cells on the ability of RA to activate PPARb/d was
then examined. Cells were transfected with either an
expression vector for CRABP-II, or with a construct har-
boring FABP5 siRNA (Figure 4C), treated with RA or
GW0742, and induction of the PPARb/d target gene
PDK-1 was monitored (Figure 4D). Overexpression of
CRABP-II had little effect on GW0742-induced expression
of PDK-1 mRNA, indicating that this protein does not
directly affect PPARb/d activity. Either overexpression of
CRABP-II or underexpression of FABP5 abolished the
ability of RA to induce PDK-1 expression. Additionally, in
accordance with the observations that GW0742 tightly
binds to FABP5 and mobilizes it to the nucleus (Figure 3),
decreasing FABP5 expression augmented the transcrip-
tional activity of this ligand. The data thus show that
increasing the CRABP-II/FABP5 ratio in HaCaT cells di-
verts RA away from PPARb/d. The involvement of FABP5
in induction of PDK-1 by both RA and GW0742 also
supports the notion that this binding protein mediates
the nuclear targeting of both of these PPARb/d ligands.
Upregulation of PDK-1 expression upon activation of
PPARb/d by RA in HaCaT cells results in the phosphoryla-
tion and thus the activation of the survival factor Akt (Fig-
ure 2E). It can thus be predicted that RA treatment will pro-
tect these cells against apoptosis. To examine this notion,
Figure 5. In HaCaT and NaF Cells Decreasing the FABP5/CRABP-II Ratio Converts RA from an Antiapoptotic to a Proapoptotic
Agent
(A) HaCaT cells were treated with denoted ligands (2 mM, 2 hr) prior to addition of TNFa (20 ng/ml, 14 hr). Cells were lysed and the level of cleaved
PARP assessed by immunoblots. A representative experiment is shown.
(B) Quantitation of data described in panel (A). Band intensities were normalized to the loading control GAPDH. Data are mean ± SEM, n = 3.
(C and D) Parental HaCaT (C) or NaF (D) cells and corresponding cells overexpressing CRABP-II or underexpressing FABP5 were treated with de-
noted ligands (1 mM, 16 hr) or pretreated with ligands for 2 hr prior to addition of TNFa (20 ng/ml, 14 hr, solid bars). Apoptosis was evaluated using
the APOPercentage Apoptosis Assay kit. Data are mean ± SEM, n = 3.HaCaT cells were treatedwith the apoptosis inducer tumor
necrosis factor a (TNFa), and the effects of RA, the PPARb/
d ligand GW0742, and the RAR ligand TTNPB on TNFa-
induced apoptosis were examined. To this end, we moni-
tored the ability of TNFa to trigger the cleavage of poly-
(ADP-ribose) polymerases (PARP), one of the earliest
proteins targeted for a specific cleavage during apoptosis
(Figures5Aand5B). TNFa treatmentsignificantly enhanced
PARP cleavage, demonstrating the efficacy of the cytokine
asanapoptosis-inducing agent in thesecells. In agreement
with a role for PPARb/d in enabling keratinocyte survival
during inflammation (Di-Poi et al., 2002; Tan et al., 2001),
activation of the receptor by GW0742 inhibited TNFa-
induced apoptosis. Similarly to GW0742, RA protected
the cells from TNFa-induced apoptosis. In contrast, the
RAR-ligand TTNPB induced apoptosis when administered
alone and augmented TNFa-induced PARP cleavage,
demonstrating that RAR displays proapoptotic activities
in these cells. Hence, in HaCaT cells, RA inhibits apoptosis
like a bona-fide PPARb/d ligand, an activity that diametri-
cally contrasts with the proapoptotic activities of RAR.
The hypothesis that CRABP-II and FABP5 control the
partitioning of RA between RAR and PPARb/d and thus
the biological activities of this hormone was further inves-
tigated by examining the outcome of changing the
CRABP-II/FABP5 ratio on the ability of RA to modulateTNFa-induced apoptosis. In these experiments, apopto-
sis was followed by monitoring the transfer of phosphati-
dylserine to the outer leaflet of the cell membrane, a
process linked to the execution phase of apoptosis. In
agreement with observations obtained by monitoring
PARP cleavage as a ‘‘readout’’ for apoptosis, treatment
of HaCaT cells with GW0742 or RA had little effect, while
the RAR-ligand TTNPB increased the fraction of apoptotic
cells (Figure 5C). Also in agreement, TNFa efficiently in-
duced apoptosis, both GW0742 and RA inhibited, and
TTNPB enhanced the response. Strikingly, overexpres-
sion of CRABP-II not only abolished the protective activity
of RA but converted it into an agent that, similarly to
TTNPB, enhanced TNFa-induced apoptosis. Reduced ex-
pression of FABP5 also negated the antiapoptotic activity
of RA. The observation that the decreased expression of
FABP5 did not quite lead to an enhancement of the apo-
ptotic response likely reflects that transfection of FABP5
siRNA reduced but did not completely inhibit the expres-
sion of the protein (Figure 4C). Similar effects were ob-
served in NaF cells, derived from mammary tumors of
the MMTVneu mouse model; RA ‘‘rescued’’ NaF cells
from TNFa-induced apoptosis, and either overexpression
of CRABP-II or underexpression of FABP5 abolished the
protective activity of RA and enhanced the apoptotic
response (Figure 5D).Cell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc. 729
Figure 6. In MCF-7 Cells, Increasing the
FABP5/CRABP-II RatioConvertsRA from
a Proapoptotic Agent to a Survival Factor
(A) MCF-7 cells were cotransfected with an
expression vector for FABP5 together with
CRABP-II siRNA and protein expression levels
monitored by immunoblotting.
(B–E) MCF-7 cells were mock transfected or
cotransfected with an expression vector for
FABP5 and with CRABP-II siRNA and treated
with RA. Levels of mRNA for BTG2 (B), cyclin
D1 (C), cyp26a (D), and PDK-1 (E) were mea-
sured by Q-PCR and normalized to 18s.
(F and G) MCF-7 cells were mock transfected
or cotranfected with an expression vector for
FABP5 and with CRABP-II siRNA. Cells were
treated with TRAIL (4 ng/ml), or RA (0.1 mM),
or both, and apoptosis was assessed by as-
sessing PARP cleavage (F) and by monitoring
transfer of phosphatidylserine to the plasma
membrane outer leaflet using the APOPercent-
age Apoptosis Assay kit (G).In MCF-7 Cells, Increasing the FABP5/CRABP-II
Ratio Converts RA from a Proapoptotic
to an Antiapoptotic Agent
Unlike HaCaT and NaF cells, the mammary carcinoma
MCF-7 cells display a high CRABP-II/FABP5 ratio (Fig-
ure 4B). To reverse this ratio, cells were cotransfected
with an expression vector for FABP5 and a construct har-
boring CRABP-II siRNA (Figure 6A). The ensuing concom-
itant increase in FABP5 and decrease in CRABP-II levels
didnot affect theexpressionofeitherRARorPPARb/d (Fig-
ure S2). Nevertheless, the reversal hampered the ability of
RA to upregulate the expression of the cell-cycle regulator
BTG2, a gene thatwas recently shown to comprise a direct
target for RAR and to be involved inmediating RA-induced
cell cycle arrest in MCF-7 cells (Donato et al., 2007) (Fig-
ure 6B). Correspondingly, the reversal abolished the ability
ofRA todownregulate theexpressionof cyclinD1, aknown
downstream target for BTG2 (Guardavaccaro et al., 2000;
Kawakubo et al., 2006; Kawakubo et al., 2004; Lim et al.,
1989) (Figure 6C). Reversing the FABP5/CRABP-II also in-
hibited RA-induced induction of the RAR target cyp26a
(Figure 6D). Remarkably, while RA had little effect on the
level of the direct PPARb/d target gene PDK-1 in parental
MCF-7 cells, the ligand significantly upregulated the ex-
pression of this survival factor upon the reversal of the ratio
of the binding proteins (Figure 6E). Hence, increasing the
FABP5/CRABP-II ratio in MCF-7 cells directed RA away
fromRAR and toward PPARb/d. Considering the disparate
nature of the RARandPPARb/d target genes, the observa-
tions suggest that the reversal of the CRABP-II/FABP5
ratio hampered growth-inhibitory activities and triggered
a survival response.
To further examine the consequences of the ‘‘switch’’ in
binding-protein profile, parental MCF-7 cells and cells in730 Cell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc.which the CRABP-II/FABP5 ratio was reversed were
treated with the apoptosis-inducing agent tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL). Apopto-
sis was monitored by following PARP cleavage (Figure 6F)
as well as by monitoring transfer of phosphatidylserine to
the outer leaflet of the cell membrane (Figure 6G). Trans-
fection of constructs encoding FABP5 and CRABP-II
siRNA resulted in PARP cleavage even in the absence of
TRAIL. The effect is likely to stem from a degree of apopto-
sis induced by the forced overexpression and was not
observed upon monitoring later apoptosis events, repre-
sentedby phosphatidylserinemembrane ‘‘flip.’’ Treatment
with TRAIL induced marked apoptosis, as judged by
both PARP cleavage and by plasma membrane events.
Addition of TRAIL in conjunction with RA had little
effect (PARP cleavage) or somewhat enhanced apoptosis
(phosphatidylserine translocation). Remarkably, both
‘‘read-outs’’ clearly demonstrated that, in cells in which
the CRABP-II/FABP5 ratio was reversed, RA treatment
markedly inhibited TRAIL-induced apoptosis. Hence, in-
creasing the FABP5/CRABP-II ratio in MCF-7 cells results
in conversion of RA from a growth-inhibitory to a prosur-
vival factor.
DISCUSSION
RA activates the nuclear receptor RAR, and in many em-
bryonic and adult tissues the biological activities of this
hormone can be traced to induction of expression of RAR
target genes. However, in some tissues, such as skin,
important functions of RA appear to be mediated by an
RAR-independent pathway, the nature of which remained
unclear. The observations presented here indicate that, in
addition to activating RAR, RA can also activate the
nuclear receptor PPARb/d and, thus, that the repertoire of
genes and cellular responses that can be controlled by this
hormone include bothRAR andPPARb/d targets. The data
show further that partitioning of RA between its two recep-
tors is regulated by cognate iLBPs; CRABP-II delivers RA
to RAR, while FABP5 shuttles the hormone to PPARb/d
(Figure 7). It should be noted that the binding affinity of
the CRABP-II/RAR pathway for RA exceeds that of the
FABP5/PPARb/d path. The interactions of RA with both
CRABP-II and RAR are characterized by Kds in the 0.1–
0.2 nM range (Dong et al., 1999; Sussman and de Lera,
2005), while both FABP5 and PPARb/d associate with
this compound at a Kd of 10–50 nM (Tan et al., 2002) (Fig-
ure 3A). It can thus be predicted that, in most cells, RA sig-
naling through RARwill predominate and that activation of
PPARb/d will become apparent only in cells that exhibit
a high FABP5/CRABP-II ratio. This indeed appears to be
the case. In MCF-7 cells, which express a low FABP5/
CRABP-II ratio, RA activates RAR, while keratinocytes
andNaF cells, which display a high FABP5/CRABP-II ratio,
respond to RA by activation of PPARb/d.
A high FABP5/CRABP-II ratio abolishes RA-triggered
upregulation of RAR target genes that mediate important
biological responses, such as cell-cycle arrest (Figures
6B and 6C). It is worth noting however that cells that dis-
play such a ratio retain the ability to induce the expression
of very efficient RAR targets, such as the RA-degrading
enzyme Cyp26a, albeit at a muted response (Figures 2G
and 6D). Hence, critical functions of RA that are mediated
by RAR, such as the ability to trigger its own degradation
Figure 7. A Model Outlining the Dual Transcriptional Activity
of RA
CRABP-II and FABP5 target RA to RAR and PPARb/d, respectively. In
cells that express a high CRABP-II/FABP5 ratio, RA is ‘‘channeled’’ to
RAR, often resulting in growth inhibition. Conversely, in the presence of
a low CRABP-II/FABP5 expression ratio, RA is targeted to PPARb/d,
thereby upregulating survival pathways.by upregulting the expression of Cyp26 (White et al.,
1996), can proceed in the background of the predominant
action of RA-evoked PPARb/d signaling.
The present work demonstrates that RA serves as a
physiological ligand for PPARb/d under some but not all
circumstances. However, this receptor displays near-
ubiquitous tissue expression (Kliewer et al., 1994), raising
the question of the nature of the ligand(s) that activate it
in tissues that do not support activation by RA. The ligand-
bindingpocket of PPARb/d ismuch larger than thepockets
of other nuclear receptors (Xu et al., 1999). It may thus
accommodatemultiple ligands, and it has been suggested
that various long chain fatty acids and eicosanoids may
serve as effective PPARb/d activators (Bucco et al., 1997).
Whether some of these ligands function as true physiolog-
ical ligands for the receptor remains to be clarified, but the
present work and the similar nature of ligands that bind to
FABPs and PPARs (Hanhoff et al., 2002; Widstrom et al.,
2001) raise the possibility that FABPs other than FABP5
may act to deliver ligands other than RA to PPARb/d and,
thus, that they may regulate the functionality of distinct
ligands in specific tissues.
When enabled, RA signaling through PPARb/d has pro-
found functional consequences. One consequence, ex-
plored here, is that such signaling evokes potent antia-
poptotic activities that overcome the growth-inhibitory
activities of RAR and allow cells to survive in the face of
powerful apoptotic agents. Hence, RA-dependent main-
tenance of skin integrity, proliferation of basal keratino-
cytes, and survival of these cells during wound repair likely
stem from a high expression level of FABP5, enabling RA
to activate PPARb/d. Activation of PPARb/d by RA also ap-
pears to underlie the facilitation of mammary tumor pro-
gression in MMTVneu mice by this hormone. In support
of this conclusion are the observations that RA functions
as antiapoptotic agent in cells derived from MMTVneu tu-
mors, that a high FABP5/CRABP-II ratio is required for this
activity, that tumor progression in MMTVneu mice is ac-
companied by marked increase in the FABP5/CRABP-II
ratio, and that decreasing this ratio by ectopic overexpres-
sion of CRABP-II triggers apoptosis and inhibits tumor de-
velopment in vivo (Manor et al., 2003). It is worth noting
in regard to this that it has been reported FABP5 is ex-
pressed in melanocytic tumors but not in normal human
melanocytes (Brouard et al., 2002), indicating that eleva-
tion in the expression of this protein and thus activation
of PPARb/d accompanies tumorigenesis in various can-
cers. While not directly addressed here, the observations
that RA is critical for neuronal survival (Henion and
Weston, 1994; Jacobs et al., 2006; Plum et al., 2001;
Rodriguez-Tebar and Rohrer, 1991; Wuarin et al., 1990)
raise the possibility that the brain may comprise another
organ in which RA signals through PPARb/d. It is interest-
ing to note regarding this possibility that the expression
level FABP5 is high during neurogenesis in the developing
rat brain (Liu et al., 2000), that this protein is required for
neuronal outgrowth in PC12 neuronal cells (Allen et al.,
2000), and that its expression is induced following nerveCell 129, 723–733, May 18, 2007 ª2007 Elsevier Inc. 731
injury (De Leon et al., 1996), suggesting an involvement in
survival/repair processes.
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